Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2019: 96.39
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39
For more details click here

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2021.10(6): 688-696
DOI: https://doi.org/10.20546/ijcmas.2021.1006.076


Incidence of SARS COV-2 & Influenza A in SARI Patients Attending Tertiary Care Hospital, Thanjavur
D. Sivasankari*, Jeyabharathi Jeyaraj kathirvelan and Eunice Swarna Jacob
Department of Microbiology, Orathanadu, Thanjavur - 614625, Tamil Nadu, India
*Corresponding author
Abstract:

The outbreak of corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is currently the peak season of common respiratory viral infections. Influenza A was one of the most common respiratory viruses, which may have caused initial false negative results of real-time reverse-transcriptase polymerase chain reaction for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) among the SARI patients. In contrast, clinicians cannot rule out SARS-CoV-2 and Influenza infection based on the clinical and laboratory findings. Therefore, clinicians must have a high index of suspicion for coinfection among COVID-19 patients. After recognizing the possible pathogens causing co-infection among COVID-19 patients, appropriate antimicrobial agents can be recommended. A total of 104 SARI patients with clinically suspected of COVID-19 in a tertiary care hospital Thanjavur were recruited from December 2020 to February 2021. Nasopharyngeal swabs, throat swabs were collected to detect SARS-CoV-2 and Influenza A virus by using real-time reverse transcription-polymerase chain reaction (RT-PCR). Clinical characteristics and laboratory test findings were acquired from medical records. All data were analysed to recognize the epidemiological patterns. Among the 104 SARI patients, 25.6%(27/104) patients with suspected COVID-19 were eventually confirmed to have SARS-CoV-2 infection, and the most frequently observed symptoms were cough (86%, 90/104) followed by Fever (84%, 88/104), breathlessness (80%,83/104), myalgia (25%,27/104), vomiting (15.3%,16/104), diarrhoea (12.5%13/104), chest pain (10.5%,11/104). There were no cases out of 104 SARI patients who were positive for Influenza (H1N1) by RT-PCR.


Keywords: Lower respiratory tracts, patients, pneumonia, World Health Organization
Download this article as Download

How to cite this article:

Sivasankari, D., Jeyabharathi Jeyaraj kathirvelan and Eunice Swarna Jacob. 2021. Incidence of SARS COV-2 & Influenza A in SARI Patients Attending Tertiary Care Hospital, Thanjavur.Int.J.Curr.Microbiol.App.Sci. 10(6): 688-696. doi: https://doi.org/10.20546/ijcmas.2021.1006.076